Reported 27 days ago
Moderna has postponed its break-even target by two years and expects sales in 2025 to be between $2.5 billion and $3.5 billion, below analysts’ expectations. This news comes as the company faces challenges in shifting focus from its COVID vaccine to new products, with delays in the regulatory process for flu and cancer vaccines. Consequently, shares dropped significantly, nearing a four-year low.
Source: YAHOO